Laurie H. Glimcher, chief executive of Dana-Farber Cancer Institute, said she would step down next month, ending an eight-year run capped by her surprise split with Dana-Farber’s longtime partner, Brigham and Women’s Hospital, and decision to build a cancer center with Beth Israel Deaconess Medical Center.
Benjamin L. Ebert, chair of Dana-Farber’s medical oncology department and a prize-winning researcher, will take over from Glimcher on Oct. 1, the Boston institute said in a statement on Tuesday. In his current role Ebert oversees more than half of Dana-Farber’s 556 faculty members and more than 80 research laboratories.
Glimcher, a highly regarded immunologist, will stay at Dana-Farber to continue her work in the lab she oversees and mentor the institute’s physicians and scientists.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
